Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anybody know what day the L/H full enrollment PR will drop? Should be this week. CYDY will be back over $4 after L/H and CD16 PR's. 100% gain in a few short weeks. But don't blink io or MHRA could drop before those two.
Exactly what lawsuits are you referring to? Are you referring to the advertisement PR fake investigations? One of them Pomerantz Law firm they tried the same scam against IMMU. IMMU was just bought out for $86 a share, there drug passed their trial.
Just saying.....
https://www.globenewswire.com/news-release/2019/02/07/1713627/0/en/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Immunomedics-Inc-IMMU.html
CYDY will be a 100% gainer in the next couple weeks after PR's drop. First one is due with L/H full enrollment, they are over half way there, only took one week.
CYDY back over $3 with PR of L/H full enrollment. The trial is probably filled now or close to it.
According to NIH CD12 is still recruiting. No failed trial would be recruiting.
https://clinicaltrials.gov/ct2/show/NCT04347239
But keep in mind CD12 trial is not even at the 1 year mark yet. Trials typically take 5 to 7 years. The reason for this is searching for what works. Now that positive data has come from the trial they have a path to approval in a matter of months. That is still extremely fast and unheard of. Is it fast enough for get rich quick investors and day traders, no, but CYDY will pay off big when approval comes.
And not only did they design, fill and complete the trial in less than a year, they did two trials CD10 and CD12. Both trials producing very valuable positive data. This is still at the beginning and is looking very promising for an approval for covid-19. The big revenue won't come from selling Leronlimab to treat covid it will come from all other ARDS illnesses. Covid will just serve as an open door.
2000% GAIN FROM THESE LEVELS WITH APPROVALS
CD12 is still recruiting
Approval from another country may come much sooner.
"could allow Company to sell leronlimab in Canada"
Leronlimab will be approved..just a matter of who approves first
24% REDUCTION IN MORTALITY IN PATIENTS WITH LERONLIMAB
That it...that's the post... Leronlimab for the win... EUA will be approved
24% reduction it mortality would have saved 120,000 lives in the U.S. alone. Yeah... CD12 will be approved for EUA.
"-24% deaths seems impressive"
It seems impressive because IT IS impressive! There's no way to spin it into something it's not. Opinions will not change the numbers.
minus 24% - minus 6 days = EUA
NIH is funding research for Longhaulers. CytoDyn should definitely be having a conversation with them.
https://www.nature.com/articles/d41586-021-00586-y
"and three FDAs denied an EUA" this is just completely false. Nothing has been denied much less EUA. EUA will be approved for Leronlimab to treat covid-19.
24% = EUA = TRIPLE DIGITS
PRIMARY ENDPOINT ALL CAUSE MORTALITY REDUCED BY 24%
For a preview on how a buyout would unfold take a look at Immunomedics when Gilead bought them. News broke over the weekend of the buyout, that Monday morning IMMU opened at the buyout price. It happens that fast, can you imagine being short CYDY and wake up the next morning and see the S/P at $150.
DON'T BLINK
How much time untill Longhaulers is filled? I'm guessing 2 weeks. One patient drove from New York to Florida last month and has been waiting to enter the trial.
Which PR firm will they use to announce long-haulers is now enrolling?
Oh no!! You mean to tell us a pre revenue biotech hires PR firms??? Absolutely unbelievable!! No biotech does that!! You're really scraping the bottom of the barrel on this one.
Longhaulers trial updated today. The trial is now recruiting. Should see a PR on this...could be combined with the CD12 EUA PR
https://clinicaltrials.gov/ct2/show/NCT04678830
EUA = TRIPLE DIGITS
Keytruda another immunotherapy did $3.7 billion in one quarter. And that's with a limited patient population. Leronlimab's basket trial covers over 20 cancers.
That is an awful lot of hundred billion dollars.
Nice! CytoDyn has American Regent putting on a second shift and Samsung building an entire plant.
The hiring frenzy continues at American Regent. New jobs posted today.
https://americanregent.wd1.myworkdayjobs.com/American_Regent_Careers
As you can see NP corrected himself in this interview. It's not only three digits, "three digits is being conservative"... So shouldn't be a problem.
Week#8 day 4- CD12 still enrolling patients, OLE and eIND are still approved.
This doesn't add up at all. If CD12 failed on endpoints why is CD12 recruiting with OLE, and Leronlimab has eIND. So your saying the FDA knows it failed...but is still allowing it to be used??
And to answer your question most longs here are invested in Leronlimab not a reputation. If a person invests in a company because management makes them happy and their drug is questionable, as in needing to change the trial, like hgen for instance, they're setting themselves up for failure.
Week#8- CD12 still recruiting, OLE and eIND still approved
Exactly, hysterical people saying CD12 will fail meanwhile the FDA is saying the complete opposite. Smart money is going with the FDA.
Day two of week#8- CD12 is still enrolling and the FDA continues to approve OLE and eIND.
Upcoming catalyst for CYDY
-EUA for covid
-Nasdaq uplist
-Longhaulers trial
-HIV BLA
-Cancer trial
-NASH trial
Just those alone are enough to make a major pharma company,... and that's still just the beginning.
The data is not hidden. The data is at the FDA. And now that the FDA has the data they are choosing to continue OLE for CD12. This can only mean one thing, it's their intention to approve Leronlimab. That's the only logical reason to allow OLE, and eIND to continue.
CD12 still recruiting, only with OLE, no plecebo, Leronlimab for every patient. FDA has CD12 data, they must like what they see otherwise OLE would be revoked and the trial stopped.
Week#8- OLE and eIND are still approved, this after the FDA has unblinded data. The FDA would have revoked OLE if the trial had failed. This is clearly a positive sign.
CD12:OLE-EIND-XW013K6=EUA